In the Matter of Todd Dobberfuhl, Rel. 34-97499(May 12, 2023) – In a settled matter, a corporate controller was charged with trading in the securities of Vaxart, Inc., based on nonpublic information about a major contract that Vaxart was entering into with trader's employer, Attwill, for production of an oral COVID-19 vaccine under development. Charges under Exchange Act Section 10(b) and Rule 10b-5. Remedies included cease-and-desist, disgorgement of approximately $73k plus prejudgment interest, and a civil penalty of approximately $73k.